bevasiranib

decreases level and activity of VEGF RNA

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

1.	Choroidal Neovascularization 05/01/2009 - "Early studies of the anti-VEGF agents, pegaptanib sodium, ranibizumab, bevacizumab, VEGF trap, and bevasiranib in the treatment of various neovascular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) have shown promising results. "
2.	Retinal Vein Occlusion 05/01/2009 - "Early studies of the anti-VEGF agents, pegaptanib sodium, ranibizumab, bevacizumab, VEGF trap, and bevasiranib in the treatment of various neovascular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) have shown promising results. "
3.	Macular Edema 05/01/2009 - "Early studies of the anti-VEGF agents, pegaptanib sodium, ranibizumab, bevacizumab, VEGF trap, and bevasiranib in the treatment of various neovascular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) have shown promising results. "
4.	Macular Degeneration (Age-Related Maculopathy) 01/01/2010 - "Bevasiranib for the treatment of wet, age-related macular degeneration." 06/01/2009 - "Bevasiranib, the first small interfering RNA agent developed for the treatment of neovascular age-related macular degeneration, has demonstrated clinical promise. "
5.	Glaucoma 02/01/2021 - "RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF-04523655 for AMD, and SYL040012 and QPI-1007 for glaucoma. "

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Ranibizumab (Lucentis)
3.	Bevacizumab (Avastin)
4.	aflibercept
5.	pegaptanib (Macugen)
6.	Small Interfering RNA (siRNA)
7.	PF-04523655